Products with Inhibitors bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1281 | Norcantharidin |
| Norcantharidin has been used to treat human cancers in China since 1984, it inhibits the canonical Wnt signal pathway in NSCLC, by activating WIF-1 via promoter demethylation; it also enhances TIMP‑2 antitumor and anti‑vasculogenic mimicry activities in GBCs through downregulating MMP‑2 and MT1‑MMP. Norcantharidin is a protein phosphatase type-2A inhibitor, which has less nephrotoxic and phlogogenic side-effects, it can inhibit both DNA synthesis and granulocyte-macrophage colony-forming cells (GM-CFC)growth and impaire the neogenesis of chromatin material and nuclear membrane during the M/G1 phase transition in K-562 cells. | |
| BCN1282 | Phytic acid |
| Phytic acid is the principal storage form of phosphorus in many plant tissues, especially bran and seeds. It can act as a cofactor in DNA repair by nonhomologous end-joining. It is a trypsin inhibitor, has chelating, antioxidant, anti-inflammatory, and neuroprotective effects, it forms an iron chelate which greatly accelerates Fe2+-mediated oxygen reduction yet blocks iron-driven hydroxyl radical generation and suppresses lipid peroxidation. High concentrations of phytic acid prevent browning and putrefaction of various fruits and vegetables by inhibiting polyphenol oxidase, it may be a substitute for presently employed preservatives. | |
| BCN1293 | 5,2',6'-Trihydroxy-6,7,8-trimethoxyflavone |
| 1. 5,2',6'-Trihydroxy-6,7,8-trimethoxyflavone (ED 50 =4.5 ug/ml ) shows cytotoxicity against L1210 cell and has inhibiting effects on ATPase from the cell. | |
| BCN1296 | Methyl gypsogenin 3-O-beta-D-glucuronopyranoside |
| Gypsogenin 3-O-beta-D-glucuronopyranoside shows inhibitory activity toward pancreatic lipase with IC50 value of 0.29 mM, and the free carboxylic acid groups in position 28 within its chemical structures are required for enhancement of pancreatic lipase inhibition. | |
| BCN1322 | 3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acid |
| 1. 3,23-Dioxo-9,19-cyclolanost-24-en-26-oic acid inhibits the MRCKα kinase with Kd50 of 3.0 uM, it also inhibits the MRCKβ kinase with Kd50 of 3.2 uM; the role of Kinases in cancer onset and progression has made kinases a target for the control of some cancers, suggests that it may possess anticancer activity. | |
